AVTE - Aerovate Therapeutics, Inc Price Target Chart

The daily price action for Aerovate Therapeutics (AVTE) on GURU.Markets is supported by scientific breakthroughs in lung therapy, with the consensus standing at 2.99. The business relies on stable demand for cardiovascular drugs that remains independent of market cycles. Automated cultivation systems guarantee the quality of substance synthesis. A highly motivated team of trial planning experts ensures the sustainable development of Aerovate Therapeutics (AVTE).

AVTE - Aerovate Analyst Consensus Forecast over the range 07/04/2022 - 04/29/2025

Analytical breakdowns for Aerovate (AVTE)

- stock value and consensus price forecast:

Stock Price aerovatetx.com|AVTE - Consensus Target

- market capitalization statistics:

Market Value Aerovate|AVTE - Real Price to Acquire Entire Company

- issuer book value statistics:

Book Price of a Share Aerovate Therapeutics|AVTE - Book Capitalization|Market-to-Book Ratio aerovatetx.com|AVTE - Company Total Assets

- business debt structure and liquidity details:

All Debt to Shareholders' Equity Ratio Aerovate Therapeutics|AVTE - Long-Term Debt to Capital|Current Liabilities to Capital Aerovate Therapeutics, Inc|AVTE - Company Aggregate Debts|Debts to Book Capitalization Aerovate|AVTE - Company Long-Term Debt|Company Short-Term Loans and Borrowings Aerovate Therapeutics|Intermediate Liquidity Ratio aerovatetx.com

- earnings and market ratios statistics:

AVTE - Net Profit|Projected Future Earnings Aerovate Therapeutics|AVTE - P/E Multiple|Projected Price to Earnings Ratio Aerovate Therapeutics Inc.|AVTE - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Aerovate|AVTE - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Aerovate Therapeutics|AVTE - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months aerovatetx.com|AVTE - Earnings growth in current year|Earnings growth forecast for next year Aerovate Therapeutics

- issuer revenue and sales details:

AVTE - Company Sales|Company Projected Revenue Volume aerovatetx.com|AVTE - P/S Multiple

General company analysis:AVTE aerovatetx.com

Finished products of Aerovate Therapeutics, Inc.

The development of Aerovate Therapeutics (AVTE) in the rare lung disease therapy segment directly impacts the business valuation revision, reflecting the current value of 2.99. By analyzing the trend of target valuations from the investment community, an investor can identify a time gap between market quotes and the average calculation of independent experts, allowing for an objective assessment of invested capital density and the asset's fundamental undervaluation.

Competitors of Aerovate Therapeutics